RAD51 and cancer: As reversal-dependent degradation was shown to be a major molecular determinant of chemosensitivity and -resistance in HR-defective tumors20, it will be essential to test the molecular phenotypes upon cancer-associated mutations in RAD51 paralogs, and thereby to possibly establish predictive parameters for chemosensitivity in this subset of HR-defective tumors.